Skip to main content
PMC home page
The EMBO Journal logoLink to The EMBO Journal
. 1998 Jul 1;17(13):3521–3533. doi: 10.1093/emboj/17.13.3521

Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants.

G Puntoriero 1, A Meola 1, A Lahm 1, S Zucchelli 1, B B Ercole 1, R Tafi 1, M Pezzanera 1, M U Mondelli 1, R Cortese 1, A Tramontano 1, G Galfre' 1, A Nicosia 1
PMCID: PMC1170689  PMID: 9649423

Abstract

The hypervariable region 1 (HVR1) of the putative envelope protein E2 of hepatitis C virus (HCV) is the most variable antigenic fragment in the whole viral genome and is mainly responsible for the large inter-and intra-individual heterogeneity of the infecting virus. It contains a principal neutralization epitope and has been proposed as the major player in the mechanism of escape from host immune response. Since anti-HVR1 antibodies are the only species shown to possess protective activity up to date, developing an effective prevention therapy is a very difficult task. We have approached the problem of HVR1 variability by deriving a consensus profile from >200 HVR1 sequences from different viral isolates and used it as a template to generate a vast repertoire of synthetic HVR1 surrogates displayed on M13 bacteriophage. This library was affinity selected using many different sera from infected patients. Phages were identified which react very frequently with patients' sera and bind serum antibodies that cross-react with a large panel of HVR1 peptides derived from natural HCV variants. When injected into experimental animals, the 'mimotopes' with the highest cross-reactivity induced antibodies which recognized the same panel of natural HVR1 variants. In these mimotopes we identified a sequence pattern responsible for the observed cross-reactivity. These data may hold the key for future development of a prophylactic vaccine against HCV.

Full Text

The Full Text of this article is available as a PDF (837.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter H. J. To C or not to C: these are the questions. Blood. 1995 Apr 1;85(7):1681–1695. [PubMed] [Google Scholar]
  2. Bartoli F., Nuzzo M., Pezzanera M., Nicosia A., Monaci P. Rapid protocol for template preparation of large numbers of clones. Biotechniques. 1996 Apr;20(4):554–558. doi: 10.2144/19962004554. [DOI] [PubMed] [Google Scholar]
  3. Bukh J., Miller R. H., Purcell R. H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 1995 Feb;15(1):41–63. doi: 10.1055/s-2007-1007262. [DOI] [PubMed] [Google Scholar]
  4. Casari G., Sander C., Valencia A. A method to predict functional residues in proteins. Nat Struct Biol. 1995 Feb;2(2):171–178. doi: 10.1038/nsb0295-171. [DOI] [PubMed] [Google Scholar]
  5. Choo Q. L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., Han J., Berger K., Thudium K., Kuo C. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1294–1298. doi: 10.1073/pnas.91.4.1294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  7. Chothia C., Lesk A. M. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol. 1987 Aug 20;196(4):901–917. doi: 10.1016/0022-2836(87)90412-8. [DOI] [PubMed] [Google Scholar]
  8. Cormack B. P., Struhl K. Regional codon randomization: defining a TATA-binding protein surface required for RNA polymerase III transcription. Science. 1993 Oct 8;262(5131):244–248. doi: 10.1126/science.8211143. [DOI] [PubMed] [Google Scholar]
  9. Cortese R., Felici F., Galfre G., Luzzago A., Monaci P., Nicosia A. Epitope discovery using peptide libraries displayed on phage. Trends Biotechnol. 1994 Jul;12(7):262–267. doi: 10.1016/0167-7799(94)90137-6. [DOI] [PubMed] [Google Scholar]
  10. Cortese R., Monaci P., Luzzago A., Santini C., Bartoli F., Cortese I., Fortugno P., Galfrè G., Nicosia A., Felici F. Selection of biologically active peptides by phage display of random peptide libraries. Curr Opin Biotechnol. 1996 Dec;7(6):616–621. doi: 10.1016/s0958-1669(96)80072-3. [DOI] [PubMed] [Google Scholar]
  11. Dente L., Cesareni G., Micheli G., Felici F., Folgori A., Luzzago A., Monaci P., Nicosia A., Delmastro P. Monoclonal antibodies that recognise filamentous phage: tools for phage display technology. Gene. 1994 Oct 11;148(1):7–13. doi: 10.1016/0378-1119(94)90227-5. [DOI] [PubMed] [Google Scholar]
  12. Farci P., Alter H. J., Govindarajan S., Wong D. C., Engle R., Lesniewski R. R., Mushahwar I. K., Desai S. M., Miller R. H., Ogata N. Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992 Oct 2;258(5079):135–140. doi: 10.1126/science.1279801. [DOI] [PubMed] [Google Scholar]
  13. Farci P., Alter H. J., Wong D. C., Miller R. H., Govindarajan S., Engle R., Shapiro M., Purcell R. H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7792–7796. doi: 10.1073/pnas.91.16.7792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H. J., Purcell R. H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15394–15399. doi: 10.1073/pnas.93.26.15394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Felici F., Castagnoli L., Musacchio A., Jappelli R., Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol. 1991 Nov 20;222(2):301–310. doi: 10.1016/0022-2836(91)90213-p. [DOI] [PubMed] [Google Scholar]
  16. Folgori A., Tafi R., Meola A., Felici F., Galfré G., Cortese R., Monaci P., Nicosia A. A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera. EMBO J. 1994 May 1;13(9):2236–2243. doi: 10.1002/j.1460-2075.1994.tb06501.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fried M. W., Hoofnagle J. H. Therapy of hepatitis C. Semin Liver Dis. 1995 Feb;15(1):82–91. doi: 10.1055/s-2007-1007265. [DOI] [PubMed] [Google Scholar]
  18. Ito T., Mukaigawa J., Zuo J., Hirabayashi Y., Mitamura K., Yasui K. Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus. J Gen Virol. 1996 May;77(Pt 5):1043–1054. doi: 10.1099/0022-1317-77-5-1043. [DOI] [PubMed] [Google Scholar]
  19. Kato N., Sekiya H., Ootsuyama Y., Nakazawa T., Hijikata M., Ohkoshi S., Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol. 1993 Jul;67(7):3923–3930. doi: 10.1128/jvi.67.7.3923-3930.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kojima M., Osuga T., Tsuda F., Tanaka T., Okamoto H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees. Virology. 1994 Nov 1;204(2):665–672. doi: 10.1006/viro.1994.1582. [DOI] [PubMed] [Google Scholar]
  21. Kumar U., Monjardino J., Thomas H. C. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology. 1994 Apr;106(4):1072–1075. doi: 10.1016/0016-5085(94)90770-6. [DOI] [PubMed] [Google Scholar]
  22. Kurosaki M., Enomoto N., Marumo F., Sato C. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. Virology. 1994 Nov 15;205(1):161–169. doi: 10.1006/viro.1994.1631. [DOI] [PubMed] [Google Scholar]
  23. Martell M., Esteban J. I., Quer J., Genescà J., Weiner A., Esteban R., Guardia J., Gómez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992 May;66(5):3225–3229. doi: 10.1128/jvi.66.5.3225-3229.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Martell M., Esteban J. I., Quer J., Vargas V., Esteban R., Guardia J., Gómez J. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol. 1994 May;68(5):3425–3436. doi: 10.1128/jvi.68.5.3425-3436.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mecchia M., Casato M., Tafi R., Filocamo G., Bonomo L., Fiorilli M., Cortese R., Migliaccio G., Nicosia A. Nonrheumatoid IgM in human hepatitis C virus-associated type II cryoglobulinemia recognize mimotopes of the CD4-like LAG-3 protein. J Immunol. 1996 Oct 15;157(8):3727–3736. [PubMed] [Google Scholar]
  26. Meola A., Delmastro P., Monaci P., Luzzago A., Nicosia A., Felici F., Cortese R., Galfrè G. Derivation of vaccines from mimotopes. Immunologic properties of human hepatitis B virus surface antigen mimotopes displayed on filamentous phage. J Immunol. 1995 Apr 1;154(7):3162–3172. [PubMed] [Google Scholar]
  27. Nara P. L., Garrity R. R., Goudsmit J. Neutralization of HIV-1: a paradox of humoral proportions. FASEB J. 1991 Jul;5(10):2437–2455. doi: 10.1096/fasebj.5.10.1712328. [DOI] [PubMed] [Google Scholar]
  28. Odeberg J., Yun Z., Sönnerborg A., Bjøro K., Uhlén M., Lundeberg J. Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients. J Infect Dis. 1997 Apr;175(4):938–943. doi: 10.1086/513995. [DOI] [PubMed] [Google Scholar]
  29. Prezzi C., Nuzzo M., Meola A., Delmastro P., Galfrè G., Cortese R., Nicosia A., Monaci P. Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients. J Immunol. 1996 Jun 1;156(11):4504–4513. [PubMed] [Google Scholar]
  30. Scarselli E., Cerino A., Esposito G., Silini E., Mondelli M. U., Traboni C. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. J Virol. 1995 Jul;69(7):4407–4412. doi: 10.1128/jvi.69.7.4407-4412.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Shimizu Y. K., Hijikata M., Iwamoto A., Alter H. J., Purcell R. H., Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol. 1994 Mar;68(3):1494–1500. doi: 10.1128/jvi.68.3.1494-1500.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Shimizu Y. K., Igarashi H., Kanematu T., Fujiwara K., Wong D. C., Purcell R. H., Yoshikura H. Sequence analysis of the hepatitis C virus genome recovered from serum, liver, and peripheral blood mononuclear cells of infected chimpanzees. J Virol. 1997 Aug;71(8):5769–5773. doi: 10.1128/jvi.71.8.5769-5773.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Shimizu Y. K., Iwamoto A., Hijikata M., Purcell R. H., Yoshikura H. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5477–5481. doi: 10.1073/pnas.89.12.5477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Silini E., Bono F., Cividini A., Cerino A., Bruno S., Rossi S., Belloni G., Brugnetti B., Civardi E., Salvaneschi L. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology. 1995 Feb;21(2):285–290. [PubMed] [Google Scholar]
  35. Simmonds P., Holmes E. C., Cha T. A., Chan S. W., McOmish F., Irvine B., Beall E., Yap P. L., Kolberg J., Urdea M. S. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993 Nov;74(Pt 11):2391–2399. doi: 10.1099/0022-1317-74-11-2391. [DOI] [PubMed] [Google Scholar]
  36. Toyoda H., Fukuda Y., Koyama Y., Takamatsu J., Saito H., Hayakawa T. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. J Hepatol. 1997 May;26(5):975–982. doi: 10.1016/s0168-8278(97)80105-5. [DOI] [PubMed] [Google Scholar]
  37. Tramontano A., Chothia C., Lesk A. M. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol. 1990 Sep 5;215(1):175–182. doi: 10.1016/S0022-2836(05)80102-0. [DOI] [PubMed] [Google Scholar]
  38. Weiner A. J., Brauer M. J., Rosenblatt J., Richman K. H., Tung J., Crawford K., Bonino F., Saracco G., Choo Q. L., Houghton M. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology. 1991 Feb;180(2):842–848. doi: 10.1016/0042-6822(91)90104-j. [DOI] [PubMed] [Google Scholar]
  39. Weiner A. J., Geysen H. M., Christopherson C., Hall J. E., Mason T. J., Saracco G., Bonino F., Crawford K., Marion C. D., Crawford K. A. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3468–3472. doi: 10.1073/pnas.89.8.3468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Weiner A., Erickson A. L., Kansopon J., Crawford K., Muchmore E., Hughes A. L., Houghton M., Walker C. M. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2755–2759. doi: 10.1073/pnas.92.7.2755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Winter G., Milstein C. Man-made antibodies. Nature. 1991 Jan 24;349(6307):293–299. doi: 10.1038/349293a0. [DOI] [PubMed] [Google Scholar]
  42. Zibert A., Kraas W., Meisel H., Jung G., Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol. 1997 May;71(5):4123–4127. doi: 10.1128/jvi.71.5.4123-4127.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. van Doorn L. J., Capriles I., Maertens G., DeLeys R., Murray K., Kos T., Schellekens H., Quint W. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol. 1995 Feb;69(2):773–778. doi: 10.1128/jvi.69.2.773-778.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

RESOURCES